-
Check the records of women who are scheduled to return to your facility for a contraceptive refill or annual well woman exam. Are you seeing empty spots in the schedule?
-
Two new actions from the Food and Drug Administration (FDA) will impact your practice.
-
Clinicians now have an approved indication in hand for use of the levonorgestrel intrauterine system Mirena (LNG IUS, Mirena, Bayer HealthCare Pharmaceuticals; Wayne, NJ), to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.
-
If medical abortion using mifepristone (Mifeprex, Danco Group) and misoprostol is offered at your facility, be sure to review a new study that asserts the safety of a particular mifepristone/misoprostol regimen.
-
As the United States gears up to combat the H1N1 flu (also known as swine flu), be sure your practice includes the latest Centers for Disease Control and Prevention (CDC) recommendations for care of pregnant women.
-
Encouraging news comes from the HIV vaccine research front, where an investigational vaccine regimen tested in a Thailand clinical trial has been shown to be well tolerated and to have a modest effect in preventing HIV infection.
-
Despite the findings of two new studies,1,2 providers should focus on the fact that two earlier, large studies have compared safety data from women using Yasmin (Bayer HealthCare Pharmaceuticals; Wayne, NJ) to that of other oral contraceptive (OC) users,3,4 family planning experts emphasize.
-
In July 2009, data from the National Vital Statistics System were published presenting a snapshot of the sexual and reproductive health of young people aged 10-24 between 2002 and 2007.
-
Get set for possible changes in human papillomavirus (HPV) vaccine use. A Food and Drug Administration (FDA) review committee has voted that clinical data support the efficacy and safety of GlaxoSmithKline's Cervarix vaccine candidate for the prevention of cervical precancers and cervical cancer related to HPV types 16 and 18 in girls and young women.
-
Research of an experimental urine test indicates that it successfully diagnoses chlamydia infection in men within the hour, which improves the ability to successfully treat the infection on the spot and prevent retransmission.
